 The first FDA-approved therapeutic monoclonal antibody was a murine IgG2a CD3 specific transplant rejection drug, OKT3 (also called muromonab), in 1986.This drug found use in solid organ transplant recipients who became steroid resistant.Hundreds of therapies are undergoing clinical trials.